Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 23, 2008

View Archived Issues

Aileron's Staple Peptide targets a novel interaction site for BAX activation

Pfizer's CP-751871 appears to be safe and well tolerated in phase II breast cancer study

Enhanced antimalarial activity for a newly identified acridone derivative

Single dose of new meningococcal vaccine shows immunological memory in African children

Safety and immunogenicity for a new malaria vaccine, MSP3-LSP, in phase Ib study

Novel antiinfective agents described in recent GSK patent

Cadence presents positive top-line results from phase III Acetavance trial

PharmaMar initiates phase II studies for Irvalec in non-small cell lung cancer

Positive phase II results reported for C-105 in MS-associated cognitive dysfunction

Supernus initiates phase III trial in refractory partial onset epileptic seizures

TopoTarget opens enrollment for first pivotal belinostat trial in PTCL

AkzoNobel to acquire 75/25 majority interest in joint venture with Nippon Kayaku

Nabi enters CRADA with USU and HJF to develop S. aureus vaccine

PTC Therapeutics initiates two clinical trials for PTC-299

Resolvyx commences phase I/II trial for novel resolvin therapeutic RX-10045

Sucampo initiates phase I SPL-017 study for peripheral arterial disease

Antisense completes dosing in mouse and primate toxicology studies of ATL-1103

Auxilium and Pfizer sign agreement to develop and commercialize Xiaflex in Europe

Biopure submits IND to FDA for phase II clinical trial of Hemopure in AML

KAI initiates enrollment in phase IIb study of KAI-9803 in STEMI

Arete Therapeutics reports positive phase I AR-9281 data in healthy volunteers

ARYx Therapeutics reports outcome of ATI-2042 trial in atrial fibrillation

Cytokinetics reports phase IIa CK-1827452 results in ischemic cardiomyopathy

Achillion patent reports new antibacterial agents

Novel monoclonal antibodies targeting IRC85 described in recent patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...